Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2023

01-03-2023 | Gestational Trophoblastic Disease | Review Article

Immune checkpoint inhibitor using in cases with gestational trophoblastic diseases

Author: Semra Paydas

Published in: Medical Oncology | Issue 3/2023

Login to get access

Abstract

Gestational trophoblastic neoplasias (GTNs) are chemosensitive disorders with very high cure rates. However, individuals with chemoresistant diseases pass away as a result of their illness, necessitating the use of innovative medications. Immune checkpoint inhibitors (ICIs) are a critical component of the strategy for the management of drug-resistant GTD due to the high rate of PD-1 expression and the paternal genetic inheritance in GTNs. Immunotherapy is mentioned as a potential therapeutic approach for chemotherapy-resistant GTD in the most recent worldwide recommendations. However, multicenter worldwide collaborative studies are required to give additional evidence to detect and identify prognostic markers due to the rarity of GTDs and the dearth of data in the literature.
Literature
1.
Angiolo G, Silvestro C, Guerrieri ME, Damiano AG. Placental site trophoblastic tumor and epithelioid trophoblastic tumor: clinical and pathological features, prognostic variables and treatment strategy. Gynecol Oncol. 2019;153:684–93.CrossRef
2.
3.
Ning F, Hou H, Morse AN, Lash GE. Understanding and management of gestational trophoblastic disease. F1000Research. 2019;8:428.CrossRef
4.
Kato M, Tanaka K, Takeuchi S. The nature of trophoblastic disease initiated by transplantation into immunosuppressed animals. Obstetric. 1982;142(5):497–505.CrossRef
5.
Smith HO, Qualls CR, Prairie BA, Padilla LA, Rayburn WF, Key CR. Trends in gestational choriocarcinoma: a 27-year perspective. Obstet Gynecol. 2003;102(5):978–87.PubMed
6.
Shanmugaratnam K, Muir CS, Tow SH, Cheng WC, Christine B, Pedersen E. Rates per 100,000 births and incidence of choriocarcinoma and malignant mole in Singapore Chinese and Malays. Comparison with connecticut Norway and Sweden. Int J Cancer. 1971;8:165–75.PubMedCrossRef
7.
Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003;4:670–8.PubMedCrossRef
8.
Elias KM, Berkowitz RS, Horowitz NS. State-of-the-art workup and initial management of newly diagnosed molar pregnancy and postmolar gestational trophoblastic neoplasia. J Natl Compr Cancer Netw. 2019;17:1396–401.CrossRef
9.
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Massuger L. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):86–93.PubMedPubMedCentralCrossRef
10.
-Abu-Rustum NR, Yashar CM, Bradley K et al (2003). Gestational Trophoblastic Neoplasia, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Online to NCCN.org.
11.
Mangili G, Lorusso D, Brown J, et al. Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2014;24(Suppl. S3):S109–16.PubMedCrossRef
12.
Mangili G, Sabetta G, Cioffi R, Rabaiotti E, Candotti G, Pella F, Candiani M, Bergamini A. Current evidence on immunotherapy for gestational trophoblastic neoplasia (GTN). Cancers (Basel). 2022;3(14):2782.CrossRef
13.
King JR, Wilson ML, Hetey S, Kiraly P, et al. Dysregulation of placental functions and immune pathways in complete hydatidiform moles. Int J Mol Sci. 2019;20:4999.PubMedPubMedCentralCrossRef
14.
Frega G, Kepp O, Turchetti D, Rizzo A, Pantaleo MA, Brandi G. Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms. Transl Oncol. 2021;12: 101224.CrossRef
15.
Szabolcsi Z, Demeter A, Kiraly P, et al. Epigenetic dysregulation of trophoblastic gene expression in gestational trophoblastic disease. Biomedicines. 2021;9:1935.PubMedPubMedCentralCrossRef
16.
Gomez S, Tabernacki T, Kobyra J, Roberts P, Chiappinelli KB. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol. 2020;65:99–113.PubMedCrossRef
17.
18.
Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. The Lancet. 2017;390:2343–5.CrossRef
19.
Fülöp V, Szigetvári I, Szepesi J, et al. 30 years’ experience in the treatment of low- risk gestational trophoblastic neoplasia in Hungary. J Reprod Med. 2010;55:253–7.PubMed
20.
Liu TL, Deppe G, Chang QT, Tan TT. Cerebral metastatic choriocarcinoma in the People’s Republic of China. Gynecol Oncol. 1983;15:166–70.PubMedCrossRef
21.
Lorch A, Neubauer A, Hackenthal M, et al. High-dose chemotherapy (HDCT) as second salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol. 2010;21:820e5.CrossRef
22.
Salman L, Bouchard-Fortier G, Covens A. Immune checkpoint inhibitors for the treatment of gestational trophoblastic neoplasia: rationale, effectiveness, and future fertility. Curr Treat Options in Oncol. 2022;23:1035–43.CrossRef
23.
Nakazaki H, Tokuyasu H, Takemoto Y, et al. Pulmonary metastatic choriocarcinoma from a burned-out testicular tumor. Intern Med. 2016;55:1481–5.PubMedCrossRef
24.
Ngan HY, Bende H, Benedet JL, Jones H, Montruccoli GC, Pecorelli S. FIGO Committee on gynecologic oncology. Gestational trophoblastic neoplasia FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003;83(Suppl S1):175–7.PubMedCrossRef
25.
Park HJ, Cho HY, Cha DH. The amniotic fluid cell-free transcriptome provides novel information about fetal development and placental cellular dynamics. Int J Mol Sci. 2021;22(5):2612.PubMedPubMedCentralCrossRef
26.
Polterauer PVS, Poetsch N, Reinthaller A, Grimm C, Bartl T. Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: a case report. Gynecol Oncol Rep. 2021;37: 100817.PubMedPubMedCentralCrossRef
27.
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Massuger L. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2018;143(Suppl 2):79–85.PubMedCrossRef
28.
Tryakin A, Fedyanin M, Bulanov A, et al. Dose-reduced first cycle of chemotherapy for prevention of lifethreatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status. J Cancer Res Clin Oncol. 2018;144:1817–23.PubMedCrossRef
29.
Powles T, Savage PM, Stebbing J, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer. 2007;12(96):732–7.CrossRef
30.
Oechsle K, Honecker F, Cheng T, et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol. 2011;22:2654e60.CrossRef
31.
Mego M, Svetlovska D, Miskovska V, et al. Phase II study of everolimus in refractory testicular germ cell tumors. Urol Oncol. 2016;34(3):122-e17.CrossRef
32.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 387(10027), 1540–1550.52-Huang M, Pinto A, Castillo RP, Slomovitz BM (2017). Complete serologic response to Pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J Clin Oncol. 2016;35:3172–4.
33.
34.
Reynaud D, Abi Nahed R, Lemaitre N, et al. NLRP7 promotes choriocarcinoma growth and progression through the establishment of an immunosuppressive microenvironment. Cancers. 2021;13:2999.PubMedPubMedCentralCrossRef
35.
Rustin GJ, Newlands ES, Begent RH, Dent J, Bagshawe KD. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 1989;7:900–3.CrossRef
36.
Clair KH, Gallegos N, Bristow RE. Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: a case for immune checkpoint salvage therapy in trophoblastic tumors. Gynecol Oncol Rep ep. 2020;1(34): 100625.CrossRef
37.
Athanassiou A, Begent RH, Newlands ES, Parker D, Rustin GJ, Bagshawe KD. Central nervous system metastases of choriocarcinoma. 23 years’ experience at charing cross hospital. Cancer. 1983;52:1728–35.PubMedCrossRef
38.
39.
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;28(8):86.CrossRef
40.
Zong L, Zhang M, WangW Wan X, Yang J, Xiang Y. PD-L1, B7–H3 and VISTA are highly expressed in gestational trophoblastic neoplasia. Histopathology. 2019;75(3):421–30.PubMedCrossRef
41.
Veras E, Kurman RJ, Wang T-L, Shih I-M. PD-L1 Expression in human placentas and gestational trophoblastic diseases. Int J Gynecol Pathol. 2017;36:146–53.PubMedPubMedCentralCrossRef
42.
Bolze PA, Patrier S, Massardier J, et al. PD-L1 Expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes. Int J Gynecol Cancer. 2017;27:554–61.PubMedCrossRef
43.
Inaguma S, Wang Z, Lasota J, et al. Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): analysis in 5536 cases revealed consistent expression in trophoblastic tumors. Am J Surg Pathol. 2016;40:1133–42.PubMedPubMedCentralCrossRef
44.
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52.PubMedPubMedCentralCrossRef
45.
Golfier F, Raudrant D, Frappart L, et al. First epidemiological data from the French Trophoblastic Disease Reference Center. Am J Obstet Gynecol. 2007;196:172.e1-172.e5.PubMedCrossRef
46.
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.PubMedCrossRef
47.
Jorgensen JT. Twenty years with personalized medicine: past, present, and future of individualized pharmacotherapy. Oncologist. 2019;2019:432–40.CrossRef
48.
Chen Y, Haiyan Ye H, Tang J, Weng Y, Zhang J, Liu J. Case report: first-line immune checkpoint inhibitor plus chemotherapy for oral metastasis in a patient with ultra high-risk gestational choriocarcinoma. Cancer Manag Res. 2022;14:1867–75.PubMedPubMedCentralCrossRef
49.
Huang M, Pinto A, Castillo RP, Slomovitz BM. Complete serologic response to pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J Clin Oncol. 2017;35:3172–4.PubMedCrossRef
50.
Clair KH, Gallegos N, Bristow RE. Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: a case for immune checkpoint salvage therapy in trophoblastic tumors. Gynecol Oncol Rep. 2020;34: 100625.PubMedPubMedCentralCrossRef
51.
Kazemi NY, Langstraat C, Weroha CS. Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: a case report and review of the literature. Gynecol Oncol Rep. 2022;39: 100923.PubMedPubMedCentralCrossRef
52.
Porter A, Barcelon JM, Budker RL, et al. Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulate. Gynecol Oncol Rep. 2021;36: 100782.PubMedPubMedCentralCrossRef
53.
You B, Bolze PA, Jean-Pierre Lotz JP, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN phase II trial. J Clin Oncol. 2020;38:3129–37.PubMedPubMedCentralCrossRef
54.
Cheng H, Zong L, Kong Y, et al. Camrelizumab plus apatinib in patients with high- risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP-01): a single arm, open-label phase 2 study. Lancet Oncol. 2021;22:1609–17.PubMedCrossRef
55.
Abu-Rustum NR, Yashar CM,Bradley K et al (2022).Gestational Trophoblastic Neoplasia, Version 1. NCCN Clinical Practice Guidelines in Oncology. Online to NCCN.org
56.
Paulino E, de Melo AC. Immunotherapy in gestational trophoblastic neoplasia: great times are coming. Int J Gynecol Cancer. 2020;30:1654–5.PubMedCrossRef
57.
Worley MJ, Elias KM, Horowitz NS, Quade BJ, Berkowitz RS. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: a case from the New England Trophoblastic Disease Center, Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Gynecol Oncol. 2018;148:5–11.PubMedCrossRef
58.
59.
Choi MC, Oh J, Lee C. Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia. Eur J Cancer. 2019;121:94–7.PubMedCrossRef
60.
Goldfarb JA, Dinoi G, Mariani A, Langstraat CL. A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab. Gynecol Oncol Rep. 2020;32: 100574.PubMedPubMedCentralCrossRef
61.
Pisani D, Calleja-Agius J, Di Fiore R, et al. Epithelioid trophoblastic tumour: a case with genetic linkage to a child born over seventeen years prior, successfully treated with surgery and pembrolizumab. Curr Oncol. 2021;28:5346–55.PubMedPubMedCentralCrossRef
62.
Bell SG, Uppal S, Sakala MD, Sciallis AP, Rolston A. An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab. Gynecol Oncol Rep. 2021;37: 100819.PubMedPubMedCentralCrossRef
63.
Moffett A, Chazara O, Colucci F. Maternal allo-recognition of the fetus. Fertil Steril. 2017;107:1269–72.PubMedCrossRef
64.
65.
Wong AJ, Finch L, Pearson JM, Pinto A, Huang M. Retreatment of chemotherapy- resistant metastatic choriocarcinoma with immunotherapy. Gynecologic Oncology Reports. 2022;40: 100955.PubMedPubMedCentralCrossRef
66.
Urosevic M, Dummer R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res. 2008;68:627–30.PubMedCrossRef
67.
Joneborg U, Coopmans L, van Trommel N, Seckl M, Lok CAR. Fertility and pregnancy outcome in gestational trophoblastic disease. Int J Gynecol Cancer. 2021;31:399–411.PubMedCrossRef
68.
Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242–50.PubMedPubMedCentralCrossRef
69.
ZengW QS, Wang R, et al. PD-L1 blockage increases fetal resorption and Tfr cells but does not affect Tfh/Tfr ratio and B-cell maturation during allogeneic pregnancy. Cell Death Dis. 2020;11:119.CrossRef
70.
Polnaszek B, Mullen M, Bligard K, Raghuraman N, Massad LS. Term pregnancy after complete response of placental site trophoblastic tumor to immunotherapy. Obstet Gynecol. 2021;138:115–8.PubMedCrossRef
Metadata
Title
Immune checkpoint inhibitor using in cases with gestational trophoblastic diseases
Author
Semra Paydas
Publication date
01-03-2023
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2023
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-022-01941-3

Other articles of this Issue 3/2023

Medical Oncology 3/2023 Go to the issue

Original Paper

B7-H6 enhances F-actin rearrangement by targeting c-MYC activation to promote medulloblastoma migration and invasion

Original Paper

Design of a potential Sema4A-based multi-epitope vaccine to combat triple-negative breast cancer: an immunoinformatic approach

Original Paper

Propionate-producing Veillonella parvula regulates the malignant properties of tumor cells of OSCC

Review Article

Photodynamic therapy in oral cancer: a review of clinical studies

Original Paper

MORC2 and MAX contributes to the expression of glycolytic enzymes, breast cancer cell proliferation and migration

Original Paper

The in vitro treatment of mesenchymal stem cells for colorectal cancer cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits